Sino-US Precision Medical Clinical Mass Spectrometry Summit is about to be held

Health is an inevitable requirement for the all-round development of mankind and a basic   condition   for economic and social development. Achieving national health and longevity is an important symbol of the country's prosperity and national rejuvenation, and the common aspiration of the people of all nationalities in the country. With the launch of the "Healthy China 2030" Planning Outline by the Chinese government, raising the people's health and promoting healthy China's construction has been mentioned at an unprecedented new height.

Clinical mass spectrometry has progressed rapidly in recent years and has gradually evolved from scientific research to industrialization. The "Clinical Mass Spectrometry Research and Industry Alliance" (hereinafter referred to as the Alliance) came into being in such an era. As we all know, clinical mass spectrometry and second-generation sequencing, accurate imaging and called the three   major detection   tools. Clinical mass spectrometry can replace the biochemical and immunological methods for the accurate detection of existing clinical markers, and can monitor the proteomics and metabolomes from the molecular layer dynamically and accurately to achieve real early warning and accurate diagnosis. After the establishment of the alliance, it will focus on the industrialization, standardization and standardization of the manufacture and application of clinical mass spectrometry, and promote clinical mass spectrometry technology to make more contributions to human health.

On the occasion of the 14th National Conference on Laboratory Medicine, the Chinese Medical Association will hold the China-US Precision Medical Clinical Mass Spectrometry   Summit and the“Clinical   Mass Spectrometry Research and Industry Alliance” preparatory launching ceremony to jointly promote the development of China's clinical mass spectrometry industry. Better serve the laboratory medicine.

The development of new technologies is inseparable from the joint efforts of top experts and scholars in the industry. The establishment of the alliance has received extensive attention and support from Chinese and American experts. Professor Wang Chengbin, Chairman of the Chinese Medical Association's Laboratory Medicine Branch, Professor Fu Weiling, Chairman of the Medical Scientific Committee of the Chinese People's Liberation Army Medical Scientific Committee, and Professor Zhu Yusheng, Chairman of the American AACC Clinical Translation Science Division will attend the conference and deliver a speech. At the same time, Professor Trent Northen, Director of the Metabolomics Technology Center of Lawrence Berkeley National Laboratory, Director Guo Yan, Director of the Laboratory of Zhongshan Hospital of Fudan University, Professor Xu Guowang, Researcher of Dalian Institute of Chemical Physics, Chinese Academy of Sciences, and Professor Li Yan, Research Fellow, Institute of Biophysics, Chinese Academy of Sciences, will Prepare for the conference to share their successful experiences and perspectives on industrial development.

In addition, during the preparations for the alliance, he was guided by many experts in the mass spectrometry industry, including Professor Zhang Yukui, Professor Chen Hongyuan, Professor Ma Yinfa, Professor Zhao Yingming, Professor Wang Zeneng, Professor Yang Yuyuan and Professor Lu Haojie. Their support will surely become a source of strength for the development of the industry.